Document is current
Any future updates will be listed below
-
Authors
El-Halfawy, Omar M. https://orcid.org/0000-0003-2829-5851
Czarny, Tomasz L.
Flannagan, Ronald S. https://orcid.org/0000-0002-3263-2227
Day, Jonathan
Bozelli, José Carlos Jr. https://orcid.org/0000-0001-9533-0886
Kuiack, Robert C. https://orcid.org/0000-0001-9677-258X
Salim, Ahmed https://orcid.org/0000-0002-2724-5126
Eckert, Philip
Epand, Richard M. https://orcid.org/0000-0002-9602-9558
McGavin, Martin J.
Organ, Michael G.
Heinrichs, David E. https://orcid.org/0000-0002-7217-2456
Brown, Eric D. https://orcid.org/0000-0002-7624-8112
-
Funding
Funding for this research was provided by:
Michael G. DeGroote Fellowship Award in Basic Biomedical Science
Ontario Research Foundation
Cystic Fibrosis Canada
Gouvernement du Canada | Canadian Institutes of Health Research (FRN-143215)
UAlberta | Canadian Glycomics Network
Canada Research Chairs
- License Information
-
More Information
Article History
Received: 3 December 2018
Revised: 17 September 2019
Accepted: 7 October 2019
First Online: 25 November 2019
Competing interests
: E.D.B., O.M.E.-H., T.L.C., J.D., M.G.O., R.S.F. and D.E.H. are inventors on a patent application on the use of MAC-545496 and analogs thereof, alone and in combination with other antibiotics, for the treatment of MRSA infections.
